ClinicalTrials.gg
CompletedNCT04056325StrongMoxiUpdated Dec 9, 2024Results posted

Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis

A Phase 2/3 interventional study of Moxidectin and Ivermectin in Strongyloides Stercoralis Infection, sponsored by Jennifer Keiser. Completed at 1 site in Lao People's Democratic Republic. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-12-09.

Sponsored by Jennifer Keiser · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
617
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This study is a phase 2, blinded and randomized clinical trial. The phase 2a trial is single blinded and conducted in Lao, while the phase 2b trial is double-blinded and conducted in Lao and Cambodia. The study aims at providing evidence on effective doses and safety of moxidectin in adults against infection with S. stercoralis in Laos (trial 2a) and efficacy and safety of moxidectin compared to ivermectin in adults against infection with S. stercoralis in Laos and Cambodia (trial 2b). The efficacy of the treatment will be assessed by collecting three stool samples once pre-treatment and once 21 days post-treatment. The stool samples will be analyzed by a quantitative Baermann assay.

Read the detailed description

This is a phase 2a single-blinded and a phase 2b double-blinded randomized clinical trial, which aims to determine efficacy and safety of (2a) seven ascending oral moxidectin dosages in 210 adults infected with S. stercoralis, namely placebo, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg in Lao and (2b) the recommended dose moxidectin (i.e. the most promising dosage identified in trial A; between 2-12 mg) in comparison to the standard treatment dose of ivermectin (200 µg/kg) in 350 adults infected with S. stercoralis in Lao and Cambodia. Embedded in the trial is a pharmacokinetic/-dynamic study with the goal to measure moxidectin disposition in adults and to determine population pharmacokinetic (PK) parameters of the optimal dose of moxidectin in the treatment of S. stercoralis.

The primary objective is to determine the dose-response of moxidectin based on cure rates (CR) against S. stercoralis and to quantify the efficacy of the recommended dose to the standard treatment (ivermectin) in adults.

The secondary objectives of the trial are: Evaluation of the safety and tolerability of the dose-dependent treatment regimes, evaluation of the safety and tolerability of moxidectin compared to ivermectin, comparison of the larvae reduction rate (LRR) of the different treatment regimens against S. stercoralis (trial 2a,b), determination of an exposure- (including Cmax, area under curve (AUC) and tmax) -response correlation of moxidectin in adults, comparison of the exposure-response of moxidectin using venous and capillary blood, evaluation of the cure rate of the different moxidectin treatment regimens against co-infection and the determination of the population PK parameters of the optimal dose of moxidectin in the treatment of S. stercoralis.

After obtaining informed consent from each individual, the medical history of the participants will be assessed with a standardized questionnaire, in addition to a clinical examination carried out by the study physician before treatment. Enrollment will be based on collection and analysis by a quantitative Baermann method (in duplicates) of three stool samples. Randomization of participants into the different treatment arms will be stratified according to intensity of infection. The adults will also be interviewed before treatment, 3 and 24 hours as well as 21 days after treatment about the occurrence of adverse events (AE). The efficacy of the treatment will be determined 21 days post-treatment by collecting another three stool samples. All stool samples will be examined with duplicate Baermann assays recorded quantitatively. Co-infection with T. trichiura, A. lumbricoides and hookworm infection will be identified using duplicate Kato-Katz thick smears on stool samples.

A subsample of adults will further be sampled using finger pricking for micro sampling at 0, 2, 4, 8, 24, and 72 hours, 7 and 21 days post treatment to evaluate pharmacokinetic parameters (trial phase 2a) and at defined time windows, that are based on the PK model earned from trial 2a (trial phase 2b). For validation of the analytical method the subsample of one study arm (8 mg, trial phase 2a) will undergo venous blood sampling in addition to finger pricking.

An available case analysis (full analysis set according to the intention to treat principle) will be performed, including all subjects with primary end point data. Supplementary, a per-protocol analysis will be conducted. CRs will be calculated as the percentage of larvae-positive subjects at baseline who become larvae-negative after treatment. Larvae per gram (LPG) stool sample will be assessed by calculating the mean of the larvae counts from the three duplicate Baermann assays and divided by the mean weighted amount of these stool samples. The LRR will be calculated following: (LRR = (1-(mean at follow-up/mean at baseline))*100) Geometric and arithmetic mean larvae counts will be calculated for the different treatment arms before and after treatment to assess the corresponding LRRs. Bootstrap resampling method with 2,000 replicates will be used to calculate 95% confidence intervals (CIs) for LRRs. Emax models using the dose finding package of the statistical software environment R will be implemented to predict the dose-response curves in terms of CRs and LRRs.

02

Conditions studied

  • Strongyloides Stercoralis Infection
03

In context

Lead sponsor

Jennifer Keiser is the lead sponsor of 17 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (≥ 18 years) infected with S. stercoralis
  • Absence of major systemic illnesses
  • Written signed by individual

Exclusion criteria

Exclusion Criteria:

  • Any abnormal medical conditions or chronic disease
  • Negative diagnostic result for S. stercoralis
  • No written by individual.
  • Pregnant and lactating women.
  • Recent use of anthelmintic drug (within past 4 weeks), attending other clinical trials during the study
  • Known allergy to study medications (i.e. moxidectin, ivermectin)
  • Currently taking medications with known interaction (i.e. for warfarin)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
617 participants (actual)

Study arms

  • Experimental
    Phase 2a - Arm A

    2 mg Moxidectin at day 0 administered orally

    Drug: Moxidectin

  • Experimental
    Phase 2a - Arm B

    4 mg Moxidectin at day 0 administered orally

    Drug: Moxidectin

  • Experimental
    Phase 2a - Arm C

    6 mg Moxidectin at day 0 administered orally

    Drug: Moxidectin

  • Experimental
    Phase 2a - Arm D

    8 mg Moxidectin at day 0 administered orally

    Drug: Moxidectin

  • Experimental
    Phase 2a - Arm E

    10 mg Moxidectin at day 0 administered orally

    Drug: Moxidectin

  • Experimental
    Phase 2a - Arm F

    12 mg Moxidectin at day 0 administered orally

    Drug: Moxidectin

  • Placebo comparator
    Phase 2a - Arm G

    matching Placebo tablet(s) at day 0 administered orally

    Drug: Placebo oral tablet

  • Experimental
    Phase 2b - Arm A

    the recommended dose moxidectin (i.e. the most promising dosage identified in phase 2a; between 2-12 mg) at day 0 administered orally + Ivermectin placebo, corresponding to Phase 2b - Arm B

    Drug: Moxidectin

  • Active comparator
    Phase 2b - Arm B

    200 µg/kg ivermectin at day 0 administered orally + Moxidectin placebo, corresponding to Phase 2b - Arm A

    Drug: Ivermectin

Interventions

  • Monotherapy, oral administration, single dose, fixed dose

  • Monotherapy, oral administration, single dose, weight dependent

  • DrugPlacebo oral tablet

    Monotherapy, oral administration, single dose, matching number of tablets

06

What researchers measure

Primary outcomes

  1. Observed Cure Rate Against Strongyloides Stercoralis

    The conversion from being larvae positive pre-treatment to larvae negative post-treatment, or cure rate (CR).

    Time frame: Phase 2a: 21-28 days after treatment; phase 2b: 14-21 days after treatment

Secondary outcomes

  1. Observed Larvae-reduction Rate (LRR) Against Strongyloides Stercoralis

    Larvae per gram (LPG) stool sample will be assessed by calculating the mean of the larvae counts from the three duplicate Baermann assays and divided by the mean weighted amount of these stool samples. The LRR will be calculated following: (LRR = (1-(mean at follow-up/mean at baseline))\*100)

    Time frame: Phase 2a: 21-28 days after treatment; phase 2b: 14-21 days after treatment

  2. Observed CRs Against Concomitant Soil-transmitted Helminth Infections - Ascaris Lumbricoides

    CRs will be calculated for Ascaris lumbricoides infections as described in primary outcome.

    Time frame: Phase 2a: 21-28 days after treatment; phase 2b: 14-21 days after treatment

  3. Observed CRs Against Concomitant Soil-transmitted Helminth Infections - Trichuris Trichiura

    CRs will be calculated for Trichuris trichiura infections as described in primary outcome.

    Time frame: Phase 2a: 21-28 days after treatment; phase 2b: 14-21 days after treatment

  4. Observed CRs Against Concomitant Soil-transmitted Helminth Infections - Hookworm

    CRs will be calculated for Hookworm infections as described in primary outcome.

    Time frame: Phase 2a: 21-28 days after treatment; phase 2b: 14-21 days after treatment

  5. Number of Participants Reporting Adverse Events

    Subjects will be kept for observation for at least 3 hours following treatment for any acute AEs. If there is any abnormal finding, the local study physician will perform a full clinical, physical and biochemical examination and findings will be recorded. An emergency kit will be available on site to treat any medical conditions that warrant urgent medical intervention. In addition patients will also be interviewed 2-3 and 24 hours and again 3-4 (phase 2a) or 2-3 (phase 2b) weeks after treatment about the occurrence of AEs. A standardized symptom questionnaire is used, that includes the recording of headache, abdominal pain, itching, nausea, vomiting, diarrhea, allergic reaction as well as any further mentioned event by the participant.

    Time frame: 2-3 hours, 24 hours, and retrospectively 21-28 days (phase 2a) or 14-21 days (phase 2b Arm A and Arm B) after treatment.

  6. Maximum Concentration (Cmax) of Moxidectin in Adults

    Upon oral intake moxidectin levels in blood will be quantified with time using a micro sampling device. Moxidectin will be quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Drug concentrations will be calculated by interpolation from a calibration curve with a foreseen limit of quantification of approximately 5 ng/ml. The PK analysis will be undertaken fitting a structural compartmental PK model.

    Time frame: 0, 2, 4, 6, 7, 24, and 72 hours, and 28 days after treatment.

  7. Time to Reach Cmax (Tmax) of Moxidectin in Adults

    Upon oral intake moxidectin levels in blood will be quantified with time using a micro sampling device. Moxidectin will be quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Drug concentrations will be calculated by interpolation from a calibration curve with a foreseen limit of quantification of approximately 5 ng/ml. The PK analysis will be undertaken fitting a structural compartmental PK model.

    Time frame: 0, 2, 4, 6, 7, 24, and 72 hours, and 28 days after treatment.

  8. Area Under the Curve (AUC) of Moxidectin in Adults

    Upon oral intake moxidectin levels in blood will be quantified with time using a micro sampling device. Moxidectin will be quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Drug concentrations will be calculated by interpolation from a calibration curve with a foreseen limit of quantification of approximately 5 ng/ml. The PK analysis will be undertaken fitting a structural compartmental PK model.

    Time frame: 0, 2, 4, 6, 7, 24, and 72 hours, and 28 days after treatment.

  9. Elimination Half Life (T1/2) of Moxidectin in Adults

    Upon oral intake moxidectin levels in blood will be quantified with time using a micro sampling device. Moxidectin will be quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Drug concentrations will be calculated by interpolation from a calibration curve with a foreseen limit of quantification of approximately 5 ng/ml. The PK analysis will be undertaken fitting a structural compartmental PK model.

    Time frame: 0, 2, 4, 6, 7, 24, and 72 hours, and 28 days after treatment.

07

Results

Posted Dec 9, 2024

Participant flow

Phase 2a
Participant flow — Phase 2a
MilestonePhase 2a - Arm A (Moxidectin 2 mg)Phase 2a - Arm B (Moxidectin 4 mg)Phase 2a - Arm C (Moxidectin 6 mg)Phase 2a - Arm D (Moxidectin 8 mg)Phase 2a - Arm E (Moxidectin 10 mg)Phase 2a - Arm F (Moxidectin 12 mg)Phase 2a - Arm G (Placebo)Phase 2b - Arm A (Moxidectin)Phase 2b - Arm B (Ivermectin)
Started3133333232303200
Completed3029322930302900
Not completed141320300
Phase 2b
Participant flow — Phase 2b
MilestonePhase 2a - Arm A (Moxidectin 2 mg)Phase 2a - Arm B (Moxidectin 4 mg)Phase 2a - Arm C (Moxidectin 6 mg)Phase 2a - Arm D (Moxidectin 8 mg)Phase 2a - Arm E (Moxidectin 10 mg)Phase 2a - Arm F (Moxidectin 12 mg)Phase 2a - Arm G (Placebo)Phase 2b - Arm A (Moxidectin)Phase 2b - Arm B (Ivermectin)
Started0000000197197
Completed0000000192189
Not completed000000058

Outcome measures

PrimaryObserved Cure Rate Against Strongyloides Stercoralis

The conversion from being larvae positive pre-treatment to larvae negative post-treatment, or cure rate (CR).

Time frame:
Phase 2a: 21-28 days after treatment; phase 2b: 14-21 days after treatment
Reported as:
Number · percentage of participants
Observed Cure Rate Against Strongyloides Stercoralis
percentage of participantsPhase 2a - Arm A (Moxidectin 2 mg)Phase 2a - Arm B (Moxidectin 4 mg)Phase 2a - Arm C (Moxidectin 6 mg)Phase 2a - Arm D (Moxidectin 8 mg)Phase 2a - Arm E (Moxidectin 10 mg)Phase 2a - Arm F (Moxidectin 12 mg)Phase 2a - Arm G (Placebo)Phase 2b - Arm A (Moxidectin)Phase 2b - Arm B (Ivermectin)
Observed Cure Rate Against Strongyloides Stercoralis73.3 (54.1 to 87.7)89.7 (72.6 to 97.8)84.4 (67.2 to 94.7)82.8 (64.2 to 94.2)96.6 (82.2 to 99.9)87.1 (70.2 to 96.4)13.8 (3.9 to 31.7)92.7 (88.1 to 96.0)92.6 (87.9 to 95.9)
SecondaryObserved Larvae-reduction Rate (LRR) Against Strongyloides Stercoralis

Larvae per gram (LPG) stool sample will be assessed by calculating the mean of the larvae counts from the three duplicate Baermann assays and divided by the mean weighted amount of these stool samples. The LRR will be calculated following: (LRR = (1-(mean at follow-up/mean at baseline))\*100)

Time frame:
Phase 2a: 21-28 days after treatment; phase 2b: 14-21 days after treatment
Reported as:
Geometric mean · percent change
Observed Larvae-reduction Rate (LRR) Against Strongyloides Stercoralis
percent changePhase 2a - Arm A (Moxidectin 2 mg)Phase 2a - Arm B (Moxidectin 4 mg)Phase 2a - Arm A (Moxidectin 6 mg)Phase 2a - Arm D (Moxidectin 8 mg)Phase 2a - Arm E (Moxidectin 10 mg)Phase 2a - Arm F (Moxidectin 12 mg)Phase 2a - Arm G (Placebo)Phase 2b - Arm A (Moxidectin)Phase 2b - Arm B (Ivermectin)
Observed Larvae-reduction Rate (LRR) Against Strongyloides Stercoralis98.4 (93.7 to 99.9)99.4 (98.1 to 100)99.8 (99.3 to 100)97.8 (93.2 to 99.9)98.6 (95.1 to 100)98.5 (95.6 to 99.9)27.0 (-2.2 to 48.3)99.6 (99.1 to 100)99.9 (99.8 to 100)
SecondaryObserved CRs Against Concomitant Soil-transmitted Helminth Infections - Ascaris Lumbricoides

CRs will be calculated for Ascaris lumbricoides infections as described in primary outcome.

Time frame:
Phase 2a: 21-28 days after treatment; phase 2b: 14-21 days after treatment
Reported as:
Number · percentage of participants
Observed CRs Against Concomitant Soil-transmitted Helminth Infections - Ascaris Lumbricoides
percentage of participantsPhase 2a - Arm A (Moxidectin 2 mg)Phase 2a - Arm B (Moxidectin 4 mg)Phase 2a - Arm C (Moxidectin 6 mg)Phase 2a - Arm D (Moxidectin 8 mg)Phase 2a - Arm E (Moxidectin 10 mg)Phase 2a - Arm F (Moxidectin 12 mg)Phase 2a - Arm G (Placebo)Phase 2b - Arm A (Moxidectin)Phase 2b - Arm B (Ivermectin)
Observed CRs Against Concomitant Soil-transmitted Helminth Infections - Ascaris Lumbricoides—0 (0 to 0)100 (100 to 100)100 (100 to 100)100 (100 to 100)0 (0 to 0)—100 (100 to 100)83.3 (40.5 to 100)
SecondaryObserved CRs Against Concomitant Soil-transmitted Helminth Infections - Trichuris Trichiura

CRs will be calculated for Trichuris trichiura infections as described in primary outcome.

Time frame:
Phase 2a: 21-28 days after treatment; phase 2b: 14-21 days after treatment
Reported as:
Number · percentage of participants
Observed CRs Against Concomitant Soil-transmitted Helminth Infections - Trichuris Trichiura
percentage of participantsPhase 2a - Arm A (Moxidectin 2 mg)Phase 2a - Arm B (Moxidectin 4 mg)Phase 2a - Arm C (Moxidectin 6 mg)Phase 2a - Arm D (Moxidectin 8 mg)Phase 2a - Arm E (Moxidectin 10 mg)Phase 2a - Arm F (Moxidectin 12 mg)Phase 2a - Arm G (Placebo)Phase 2b - Arm A (Moxidectin)Phase 2b - Arm B (Ivermectin)
Observed CRs Against Concomitant Soil-transmitted Helminth Infections - Trichuris Trichiura1001005033000100100
SecondaryObserved CRs Against Concomitant Soil-transmitted Helminth Infections - Hookworm

CRs will be calculated for Hookworm infections as described in primary outcome.

Time frame:
Phase 2a: 21-28 days after treatment; phase 2b: 14-21 days after treatment
Reported as:
Number · percentage of participants
Observed CRs Against Concomitant Soil-transmitted Helminth Infections - Hookworm
percentage of participantsPhase 2a - Arm A (Moxidectin 2 mg)Phase 2a - Arm B (Moxidectin 4 mg)Phase 2a - Arm C (Moxidectin 6 mg)Phase 2a - Arm D (Moxidectin 8 mg)Phase 2a - Arm E (Moxidectin 10 mg)Phase 2a - Arm F (Moxidectin 12 mg)Phase 2a - Arm G (Placebo)Phase 2b - Arm A (Moxidectin)Phase 2b - Arm B (Ivermectin)
Observed CRs Against Concomitant Soil-transmitted Helminth Infections - Hookworm0111401029031.917.5
SecondaryNumber of Participants Reporting Adverse Events

Subjects will be kept for observation for at least 3 hours following treatment for any acute AEs. If there is any abnormal finding, the local study physician will perform a full clinical, physical and biochemical examination and findings will be recorded. An emergency kit will be available on site to treat any medical conditions that warrant urgent medical intervention. In addition patients will also be interviewed 2-3 and 24 hours and again 3-4 (phase 2a) or 2-3 (phase 2b) weeks after treatment about the occurrence of AEs. A standardized symptom questionnaire is used, that includes the recording of headache, abdominal pain, itching, nausea, vomiting, diarrhea, allergic reaction as well as any further mentioned event by the participant.

Time frame:
2-3 hours, 24 hours, and retrospectively 21-28 days (phase 2a) or 14-21 days (phase 2b Arm A and Arm B) after treatment.
Reported as:
Count of participants · Participants
Number of Participants Reporting Adverse Events
ParticipantsPhase 2a - Arm A (Moxidectin 2 mg)Phase 2a - Arm B (Moxidectin 4 mg)Phase 2a - Arm C (Moxidectin 6 mg)Phase 2a - Arm D (Moxidectin 8 mg)Phase 2a - Arm E (Moxidectin 10 mg)Phase 2a - Arm F (Moxidectin 12 mg)Phase 2a - Arm G (Placebo)Phase 2b - Arm A (Moxidectin)Phase 2b - Arm B (Ivermectin)
2-3 hours: Headache1111205119
2-3 hours: Abdominal pain00002011210
2-3 hours: Itching011000124
2-3 hours: Nausea000000130
2-3 hours: Vomiting000000000
2-3 hours: Diarrhea000000000
2-3 hours: Allergic reaction000000000
24 hours: Headache0000001712
24 hours: Abdominal pain00000002121
24 hours: Itching000000053
24 hours: Nausea000000030
24 hours: Vomiting000000076
24 hours: Diarrhea010010103
24 hours: Allergic reaction000100000
21-28/14-21 days: Headache211221281
21-28/14-21 days: Abdominal pain0000000125
21-28/14-21 days: Itching010000091
21-28/14-21 days: Nausea000000021
21-28/14-21 days: Vomiting000000100
21-28/14-21 days: Diarrhea110100022
21-28/14-21 days: Allergic reaction000000003
SecondaryMaximum Concentration (Cmax) of Moxidectin in Adults

Upon oral intake moxidectin levels in blood will be quantified with time using a micro sampling device. Moxidectin will be quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Drug concentrations will be calculated by interpolation from a calibration curve with a foreseen limit of quantification of approximately 5 ng/ml. The PK analysis will be undertaken fitting a structural compartmental PK model.

Time frame:
0, 2, 4, 6, 7, 24, and 72 hours, and 28 days after treatment.
Reported as:
Median · ng/mL
Maximum Concentration (Cmax) of Moxidectin in Adults
ng/mLPhase 2a - Arm A (Moxidectin 2 mg)Phase 2a - Arm B (Moxidectin 4 mg)Phase 2a - Arm C (Moxidectin 6 mg)Phase 2a - Arm D (Moxidectin 8 mg)Phase 2a - Arm E (Moxidectin 10 mg)Phase 2a - Arm F (Moxidectin 12 mg)Phase 2a - Arm G (Placebo)Phase 2b - Arm A (Moxidectin)Phase 2b - Arm B (Ivermectin)
Maximum Concentration (Cmax) of Moxidectin in Adults———86.1 (76.7 to 89.5)—————
SecondaryTime to Reach Cmax (Tmax) of Moxidectin in Adults

Upon oral intake moxidectin levels in blood will be quantified with time using a micro sampling device. Moxidectin will be quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Drug concentrations will be calculated by interpolation from a calibration curve with a foreseen limit of quantification of approximately 5 ng/ml. The PK analysis will be undertaken fitting a structural compartmental PK model.

Time frame:
0, 2, 4, 6, 7, 24, and 72 hours, and 28 days after treatment.
Reported as:
Median · hours
Time to Reach Cmax (Tmax) of Moxidectin in Adults
hoursPhase 2a - Arm A (Moxidectin 2 mg)Phase 2a - Arm B (Moxidectin 4 mg)Phase 2a - Arm C (Moxidectin 6 mg)Phase 2a - Arm D (Moxidectin 8 mg)Phase 2a - Arm E (Moxidectin 10 mg)Phase 2a - Arm F (Moxidectin 12 mg)Phase 2a - Arm G (Placebo)Phase 2b - Arm A (Moxidectin)Phase 2b - Arm B (Ivermectin)
Time to Reach Cmax (Tmax) of Moxidectin in Adults———4 (4 to 4)—————
SecondaryArea Under the Curve (AUC) of Moxidectin in Adults

Upon oral intake moxidectin levels in blood will be quantified with time using a micro sampling device. Moxidectin will be quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Drug concentrations will be calculated by interpolation from a calibration curve with a foreseen limit of quantification of approximately 5 ng/ml. The PK analysis will be undertaken fitting a structural compartmental PK model.

Time frame:
0, 2, 4, 6, 7, 24, and 72 hours, and 28 days after treatment.
Reported as:
Median · ng/mL*h
Area Under the Curve (AUC) of Moxidectin in Adults
ng/mL*hPhase 2a - Arm A (Moxidectin 2 mg)Phase 2a - Arm B (Moxidectin 4 mg)Phase 2a - Arm C (Moxidectin 6 mg)Phase 2a - Arm D (Moxidectin 8 mg)Phase 2a - Arm E (Moxidectin 10 mg)Phase 2a - Arm F (Moxidectin 12 mg)Phase 2a - Arm G (Placebo)Phase 2b - Arm A (Moxidectin)Phase 2b - Arm B (Ivermectin)
Area Under the Curve (AUC) of Moxidectin in Adults———5028 (4286 to 5578)—————
SecondaryElimination Half Life (T1/2) of Moxidectin in Adults

Upon oral intake moxidectin levels in blood will be quantified with time using a micro sampling device. Moxidectin will be quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Drug concentrations will be calculated by interpolation from a calibration curve with a foreseen limit of quantification of approximately 5 ng/ml. The PK analysis will be undertaken fitting a structural compartmental PK model.

Time frame:
0, 2, 4, 6, 7, 24, and 72 hours, and 28 days after treatment.
Reported as:
Median · hours
Elimination Half Life (T1/2) of Moxidectin in Adults
hoursPhase 2a - Arm A (Moxidectin 2 mg)Phase 2a - Arm B (Moxidectin 4 mg)Phase 2a - Arm C (Moxidectin 6 mg)Phase 2a - Arm D (Moxidectin 8 mg)Phase 2a - Arm E (Moxidectin 10 mg)Phase 2a - Arm F (Moxidectin 12 mg)Phase 2a - Arm G (Placebo)Phase 2b - Arm A (Moxidectin)Phase 2b - Arm B (Ivermectin)
Elimination Half Life (T1/2) of Moxidectin in Adults———666 (562 to 759)—————

Adverse events

Collected over 21-28 days (phase 2a) / 14-21 days (phase 2b). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 2a - Arm A (Moxidectin 2 mg)0/31 (0%)0/31 (0%)3/31 (9.7%)
Phase 2a - Arm B (Moxidectin 4 mg)0/33 (0%)0/33 (0%)6/33 (18.2%)
Phase 2a - Arm C (Moxidectin 6 mg)0/33 (0%)0/33 (0%)3/33 (9.1%)
Phase 2a - Arm D (Moxidectin 8 mg)0/32 (0%)0/32 (0%)5/32 (15.6%)
Phase 2a - Arm E (Moxidectin 10 mg)0/32 (0%)0/32 (0%)7/32 (21.9%)
Phase 2a - Arm F (Moxidectin 12 mg)0/30 (0%)0/30 (0%)1/30 (3.3%)
Phase 2a - Arm G (Placebo)0/32 (0%)0/32 (0%)12/32 (37.5%)
Phase 2b - Arm A (Moxidectin)0/197 (0%)0/197 (0%)59/197 (29.9%)
Phase 2b - Arm B (Ivermectin)0/197 (0%)0/197 (0%)60/197 (30.5%)
Most frequent other events
Most frequent other events
EventPhase 2a - Arm A (Moxidectin 2 mg)Phase 2a - Arm B (Moxidectin 4 mg)Phase 2a - Arm C (Moxidectin 6 mg)Phase 2a - Arm D (Moxidectin 8 mg)Phase 2a - Arm E (Moxidectin 10 mg)Phase 2a - Arm F (Moxidectin 12 mg)Phase 2a - Arm G (Placebo)Phase 2b - Arm A (Moxidectin)Phase 2b - Arm B (Ivermectin)
HeadacheGeneral disorders3/312/332/333/324/321/308/3225/19721/197
Abdominal painGastrointestinal disorders0/310/330/330/322/320/301/3241/19734/197
ItchingSkin and subcutaneous tissue disorders0/312/331/330/320/320/301/3215/1978/197
DiarrheaGastrointestinal disorders1/312/330/331/321/320/301/322/1975/197
VomitingGastrointestinal disorders0/310/330/330/320/320/301/327/1976/197
NauseaGeneral disorders0/310/330/330/320/320/301/326/1972/197
Allergic reactionGeneral disorders0/310/330/331/320/320/300/320/1973/197

Baseline characteristics

Age, Continuous
Age, Continuous(years)Phase 2a - Arm A (Moxidectin 2 mg)Phase 2a - Arm B (Moxidectin 4 mg)Phase 2a - Arm C (Moxidectin 6 mg)Phase 2a - Arm D (Moxidectin 8 mg)Phase 2a - Arm E (Moxidectin 10 mg)Phase 2a - Arm F (Moxidectin 12 mg)Phase 2a - Arm G (Placebo)Phase 2b - Arm A (Moxidectin)Phase 2b - Arm B (Ivermectin)Total
Mean41.6 ± 10.746.3 ± 12.545.3 ± 11.844.0 ± 13.544.4 ± 11.844.3 ± 11.240.0 ± 10.745.4 ± 11.644.8 ± 11.145.1 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)Phase 2a - Arm A (Moxidectin 2 mg)Phase 2a - Arm B (Moxidectin 4 mg)Phase 2a - Arm C (Moxidectin 6 mg)Phase 2a - Arm D (Moxidectin 8 mg)Phase 2a - Arm E (Moxidectin 10 mg)Phase 2a - Arm F (Moxidectin 12 mg)Phase 2a - Arm G (Placebo)Phase 2b - Arm A (Moxidectin)Phase 2b - Arm B (Ivermectin)Total
Female128109139108994254
Male18212220172119108103349
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Phase 2a - Arm A (Moxidectin 2 mg)Phase 2a - Arm B (Moxidectin 4 mg)Phase 2a - Arm C (Moxidectin 6 mg)Phase 2a - Arm D (Moxidectin 8 mg)Phase 2a - Arm E (Moxidectin 10 mg)Phase 2a - Arm F (Moxidectin 12 mg)Phase 2a - Arm G (Placebo)Phase 2b - Arm A (Moxidectin)Phase 2b - Arm B (Ivermectin)Total
Count of participants—————————0
Region of Enrollment
Region of Enrollment(participants)Phase 2a - Arm A (Moxidectin 2 mg)Phase 2a - Arm B (Moxidectin 4 mg)Phase 2a - Arm C (Moxidectin 6 mg)Phase 2a - Arm D (Moxidectin 8 mg)Phase 2a - Arm E (Moxidectin 10 mg)Phase 2a - Arm F (Moxidectin 12 mg)Phase 2a - Arm G (Placebo)Phase 2b - Arm A (Moxidectin)Phase 2b - Arm B (Ivermectin)Total
Laos31333332323032197197617
Strongyloides stercoralis infection intensity
Strongyloides stercoralis infection intensity(Participants)Phase 2a - Arm A (Moxidectin 2 mg)Phase 2a - Arm B (Moxidectin 4 mg)Phase 2a - Arm C (Moxidectin 6 mg)Phase 2a - Arm D (Moxidectin 8 mg)Phase 2a - Arm E (Moxidectin 10 mg)Phase 2a - Arm F (Moxidectin 12 mg)Phase 2a - Arm G (Placebo)Phase 2b - Arm A (Moxidectin)Phase 2b - Arm B (Ivermectin)Total
Light64635344753131
Moderate131314121213128583257
Heavy111212141314136561215
08

Study locations

1 site
  • National Institute of Public Health
    Vientiane, Lao People's Democratic Republic
09

References and documents

Publications

  • Smit C, Hofmann D, Sayasone S, Keiser J, Pfister M. Characterization of the Population Pharmacokinetics of Moxidectin in Adults Infected with Strongyloides Stercoralis: Support for a Fixed-Dose Treatment Regimen. Clin Pharmacokinet. 2022 Jan;61(1):123-132. doi: 10.1007/s40262-021-01048-4. Epub 2021 Jul 23. PubMed 34296417 ↗
  • Hofmann D, Sayasone S, Sengngam K, Chongvilay B, Hattendorf J, Keiser J. Efficacy and safety of ascending doses of moxidectin against Strongyloides stercoralis infections in adults: a randomised, parallel-group, single-blinded, placebo-controlled, dose-ranging, phase 2a trial. Lancet Infect Dis. 2021 Aug;21(8):1151-1160. doi: 10.1016/S1473-3099(20)30691-5. Epub 2021 Mar 30. PubMed 33798487 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Apr 2021, 17 months.

Results were first posted in Dec 2024, 3 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2019
First posted
Aug 14, 2019
StartActual
Nov 27, 2019
Primary completionActual
Apr 30, 2021
CompletionActual
Apr 30, 2021
Results first posted
Dec 9, 2024
Last update
Dec 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04056325
Lead sponsor
Jennifer Keiser
Collaborators
National Institute of Public Health, Vientiane, Laos
Responsible party
Jennifer Keiser (Prof. Jennifer Keiser, PhD, Swiss Tropical & Public Health Institute) — Sponsor-investigator
First posted
Aug 14, 2019
Start date
Nov 27, 2019
Primary completion
Apr 30, 2021
Completion
Apr 30, 2021
Results posted
Dec 9, 2024
Last update
Dec 9, 2024

Study contacts

Jennifer Keiser, Prof. Dr.
principal investigator · Swiss TPH

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxidectin

Start the discussion